We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nektar (NKTR) Moves 18.3% Higher: Will This Strength Last?
Read MoreHide Full Article
Nektar Therapeutics (NKTR - Free Report) shares soared 18.3% in the last trading session to close at $100.35. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 17.5% gain over the past four weeks.
The stock rallied after the company announced new data from a blinded 16-week treatment extension period of its phase IIb REZOLVE-AA study, evaluating rezpeg in patients with severe-to-very-severe alopecia areata. The 52-week top-line data from the 16-week blinded treatment extension of the REZOLVE-AA study demonstrated deepening of responses in severe-to-very-severe alopecia areata following treatment with rezpeg.
This biopharmaceutical company is expected to post quarterly loss of $1.73 per share in its upcoming report, which represents a year-over-year change of +47.6%. Revenues are expected to be $11.39 million, up 8.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Nektar, the consensus EPS estimate for the quarter has been revised 10.9% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on NKTR going forward to see if this recent jump can turn into more strength down the road.
Nektar is part of the Zacks Medical - Drugs industry. Ironwood Pharmaceuticals (IRWD - Free Report) , another stock in the same industry, closed the last trading session 0.2% lower at $4.42. IRWD has returned 45.7% in the past month.
For Ironwood, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.07. This represents a change of +150% from what the company reported a year ago. Ironwood currently has a Zacks Rank of #3 (Hold).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Nektar (NKTR) Moves 18.3% Higher: Will This Strength Last?
Nektar Therapeutics (NKTR - Free Report) shares soared 18.3% in the last trading session to close at $100.35. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 17.5% gain over the past four weeks.
The stock rallied after the company announced new data from a blinded 16-week treatment extension period of its phase IIb REZOLVE-AA study, evaluating rezpeg in patients with severe-to-very-severe alopecia areata. The 52-week top-line data from the 16-week blinded treatment extension of the REZOLVE-AA study demonstrated deepening of responses in severe-to-very-severe alopecia areata following treatment with rezpeg.
This biopharmaceutical company is expected to post quarterly loss of $1.73 per share in its upcoming report, which represents a year-over-year change of +47.6%. Revenues are expected to be $11.39 million, up 8.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Nektar, the consensus EPS estimate for the quarter has been revised 10.9% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on NKTR going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Nektar is part of the Zacks Medical - Drugs industry. Ironwood Pharmaceuticals (IRWD - Free Report) , another stock in the same industry, closed the last trading session 0.2% lower at $4.42. IRWD has returned 45.7% in the past month.
For Ironwood, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.07. This represents a change of +150% from what the company reported a year ago. Ironwood currently has a Zacks Rank of #3 (Hold).